CHICAGO -- Gene therapy for Danon disease, a rare inherited cause of hypertrophic cardiomyopathy, appeared to improve or ...
Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...
Medpage Today on MSN21h
Big Blow to Anticoagulation Strategy Against Afib-Related Cognition ProblemsCHICAGO -- Researchers failed to prevent cognitive impairment in people with existing atrial fibrillation (Afib) by going the ...
In a report released today, Mohit Bansal from Wells Fargo maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report), with a ...
We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at ...
Bristol Myers reports promising preliminary results for its next-gen CAR T therapy CC-97540, showing safety and early efficacy in a Phase 1 study for severe autoimmune diseases.
AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...
Patients with GPA completely weaned off glucocorticoids were four times as likely to flare compared with those kept on a low ...
Bristol Myers Squibb Co. shares surged on Monday after rival AbbVie Inc. reported disappointing results from the trial of a new schizophrenia drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback